Thermographic and symptomatic effect of a single dose of sildenafil citrate on Raynaud's phenomenon in patients with systemic sclerosis: A potential treatment [10]

Journal of Rheumatology

Volumn 33, Issue 9, 2006, Pages 1918-1919

  Kumar, Namita ^a   Griffiths, Bridget ^a   Allen, John ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SILDENAFIL;

ADULT; CLINICAL ARTICLE; CLINICAL TRIAL; COLD EXPOSURE; DETERIORATION; DISEASE EXACERBATION; DRUG DOSE REGIMEN; FEMALE; HEADACHE; HUMAN; HYPOTENSION; LETTER; PALLIATIVE THERAPY; PILOT STUDY; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SINGLE DRUG DOSE; SKIN TEMPERATURE; SYSTEMIC SCLEROSIS; THERMOGRAPHY; TREATMENT RESPONSE;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PURINES; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; SKIN TEMPERATURE; SULFONES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 33748561837     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (2)

1. Coleiro B, Marshall SE, Denton CP, et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology Oxford 2001;40:1038-43.
2. American College of Rheumatology Preliminary criteria for Systemic Sclerosis. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.